- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02071121
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
January 29, 2015 updated by: Biogen
A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
The primary objective of this study is to evaluate the safety and tolerability of single doses of BIIB061 administered to healthy adult volunteers.
Secondary objectives in this study population are to determine the single-dose pharmacokinetic (PK) profile and the absolute bioavailability (Fabs) of BIIB061 and to determine the effects of food intake (high-fat, high-calorie meal) on BIIB061 PK and safety.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47710
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Males and postmenopausal (defined as no menses for 12 months and confirmed by follicle-stimulating hormone (FSH) levels determined at screening to be in the postmenopausal range) or surgically sterile females.
- All males must practice effective contraception during the study and be willing and able to continue male contraception for 3 months after the dose of study treatment. All male participants must also be willing to refrain from sperm donation for at least 3 months after their last dose of study treatment. Note: Females of childbearing potential, are not allowed to enter the study.
- Must be in good health and have normal vital signs as determined by the Investigator.
- Participants agree to abstain from alcohol ingestion for the duration of time that they are in the study.
- Must be a nonsmoker and must not use chewing tobacco or nicotine products, for at least 3 months prior to Day -1.
- Must have a body mass index (BMI) of 18 to 30 kg/m2, inclusive.
Key Exclusion Criteria:
- History of or positive test result at screening for human immunodeficiency virus (HIV).
- History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, oncologic, or other major disease, as determined by the Investigator.
- Clinically significant (as determined by the Investigator) 12-lead electrocardiogram (ECG) abnormalities, including corrected QT interval using Fridericia's correction method of >450 ms for males and >470 ms for females.
- History of severe allergic or anaphylactic reactions.
- Serious infection (e.g., pneumonia, septicemia) as determined by the Investigator, within 3 months prior to Day -1.
- Consumption of grapefruit or grapefruit-containing products within 3 days of dosing.
- Treatment with any over-the-counter products, including herbal and/or alternative health preparations and procedures within the 14 days prior to Day -1.
- Current enrollment in any other drug, biologic, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to Day -1.
- Blood donation (1 unit or more) within 30 days prior to Day -1
- History of drug or alcohol abuse (as determined by the Investigator), a positive urine drug/alcohol test, or a positive cotinine test at Screening or Day -1, or alcohol use within 48 hours (as reported by the subject) prior to Day -1.
- Vigorous exercise (as determined by the Investigator) within 48 hours prior to Day -1.
- History of malignant disease, including solid tumors and hematologic malignancies.
- Surgery within 3 months prior to Day-1.
- History of seizures other than childhood febrile seizure.
- Inability or unwillingness to comply with study requirements.
NOTE: Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Fasted participants will receive a single oral dose of placebo to BIIB061.
|
BIIB061 matching placebo capsules
|
Experimental: BIIB061 3 mg
Fasted participants will receive a single oral dose of BIIB061 3 mg.
|
BIIB061 capsules for oral administration
|
Experimental: BIIB061 10 mg
Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
|
BIIB061 capsules for oral administration
Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
|
Experimental: BIIB061 30 mg
Fasted participants will receive a single oral dose of BIIB061 30 mg.
Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
|
BIIB061 capsules for oral administration
|
Experimental: BIIB061 60 mg
Fasted participants will receive a single oral dose of BIIB061 60 mg.
|
BIIB061 capsules for oral administration
|
Experimental: BIIB061 100 mg
Fasted participants will receive a single oral dose of BIIB061 100 mg.
|
BIIB061 capsules for oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants that experience adverse events (AEs) and Serious Adverse Events (SAEs)
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration-time curve from time 0 to infinity (AUCinf) of BIIB061
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Maximum observed concentration (Cmax) of BIIB061
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Time to reach maximum observed concentration (Tmax) of BIIB061
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Half-life (t1/2) of BIIB061
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Absolute bioavailability (Fabs) of BIIB061 for the absolute bioavailability cohort only
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Clearance of BIIB061 for the absolute bioavailability cohort only.
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
Volume of distribution (Vd) of BIIB061 for the absolute bioavailability cohort only.
Time Frame: Predose and up to 28 days post-dose.
|
Predose and up to 28 days post-dose.
|
|
The difference between PK parameters (AUC, Cmax, Tmax, and t1/2) taken under fasting conditions and following a high-fat, high-calorie meal are analyzed
Time Frame: Day 1 to Week 4 (28-day fasting PK measurements), a washout period followed by dosing after a high-fat, high-calorie meal (28-day PK measurements)
|
For the fasting PK portion of the study, participants' PK samples are taken after an overnight fast of at least 10 hours.
For the food effect portion of the study, the dose is given 30 minutes following a high-fat, high-calorie meal.
|
Day 1 to Week 4 (28-day fasting PK measurements), a washout period followed by dosing after a high-fat, high-calorie meal (28-day PK measurements)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
February 21, 2014
First Submitted That Met QC Criteria
February 21, 2014
First Posted (Estimate)
February 25, 2014
Study Record Updates
Last Update Posted (Estimate)
February 2, 2015
Last Update Submitted That Met QC Criteria
January 29, 2015
Last Verified
October 1, 2014
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States